Photodynamic and Pharmacologic Treatment of CNV
Photodynamic and Pharmacologic Treatment of Choroidal Neovascularization (Photodynamic Booster Study)
PhasePhase 1/Phase 2
Lead SponsorMid-Atlantic Retina Consultations, Inc.
StatusCompleted No Results Posted
Indication/ConditionChoroidal Neovascularization Macular Degeneration
Intervention/Treatmentranibizumab verteporfin ...
The goal of this pilot study is to validate the use of the combination of Lucentis (ranibizumab) and Visudyne (verteporfin) in the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and to explore the use of a volumetric analysis of the CNV lesion to determine disease activity, response to therapy, and as a tool for determining the need for retreatment.
Verteporfin (Visudyne) 6 mg/m2 at 300mW/cm2 given on week O and then at week 5, given as indicated per protocol; ranibizumab (Lucentis) 0.3 mg given at week 1
ranibizumab (Lucentis) 0.3 mg on weeks 1,5,9,13,17,21,25,29,33&37 per study protocol
Combined treatment with verteporfin (Visudyne) and ranibizumab (Lucentis)
Treatment with ranibizumab (Lucentis)
Inclusion Criteria: All previously untreated CNV secondary to MD